We are an RNA technology company, with over 30 years’ experience, offering professional partnerships to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage, and late stage projects using our proprietary platforms across RNA chemistry, LNP formulation, and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.
Our innovative proprietary LNP platforms are tailored for specific routes of administration, intravenous (IV), intra-tumoral (IT) and intramuscular (IM), allowing better targeted biodistribution. Studies have demonstrated substantial mRNA payload distribution to target tissue.
Our proprietary mRNA chemistry platform technology enable sequence engineering of mRNA constructs to ensure optimal mRNA translation efficiency and maximal mRNA stability. Sequence engineering can be tuned to enable immune silent or immune-stimulatory mRNA, in addition, constructs can be optimized for improved tissue specific expression.
Differentiated mRNA capabilities and innovative, differentiated lipid formulations that enable targeted delivery and tailored biodistribution.
The continuation of our pipeline products, from IV administered HPC16+ cancer treatment (clinically ready), to intra tumoral platform containing proprietary immune-activating mix and ex vivo activation of dendritic cells for oncology (phase 2 data available).
More than 30 years experience of manufacturing research grade RNA, and more than 5 years of GMP RNA production experience in our cGMP accredited RNA production facility in Niel, Belgium.
